Alimera Sciences, Inc. (ALIM)

0.87
0.02 1.97
NASDAQ
Prev Close 0.89
Open 0.88
Day Low/High 0.86 / 0.88
52 Wk Low/High 0.72 / 1.34
Volume 256.39K
Exchange NASDAQ
Shares Outstanding 70.97B
Market Cap 63.87M
Div & Yield N.A. (N.A)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARES, HPR, IDCC, INS, IOR, RXN, TCI, TEO, TSU, VST, WMK Downgrades: ALIM, BBGI, CAG, CBM, CNDT, DEI, FNJN, NNBR, PENN Initiations: LOMA, NVMM Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa

TheStreet Quant Rating: D (Sell)